{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:27:34Z","timestamp":1789205254144,"version":"build-2803163510"},"reference-count":127,"publisher":"Portland Press Ltd.","issue":"3","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,5,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Genodermatoses constitute a clinically heterogeneous group of devastating genetic skin disorders. Currently, therapy options are largely limited to symptomatic treatments and although significant advances have been made in ex vivo gene therapy strategies, various limitations remain. However, the recent technical transformation of the genome editing field promises to overcome the hurdles associated with conventional gene addition approaches. In this review, we discuss the need for developing novel treatments and describe the current status of gene editing for genodermatoses, focusing on a severe blistering disease called epidermolysis bullosa (EB), for which significant progress has been made. Initial research utilized engineered nucleases such as transcription activator-like effector nucleases and meganucleases. However, over the last few years, clustered regularly interspaced short palindromic repeats\/CRISPR-associated protein 9 (CRISPR\/Cas9) have upstaged older generation gene editing tools. We examine different strategies for CRISPR\/Cas9 application that can be employed depending on the type and position of the mutation as well as the mode of its inheritance. Promising developments in the field of base editing opens new avenues for precise correction of single base substitutions, common in EB and other genodermatoses. We also address the potential limitations and challenges such as safety concerns and delivery efficiency. This review gives an insight into the future of gene editing technologies for genodermatoses.<\/jats:p>","DOI":"10.1042\/etls20180148","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T13:45:19Z","timestamp":1554471919000},"page":"313-326","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["CRISPR\/Cas9 gene editing for genodermatoses: progress and perspectives"],"prefix":"10.1042","volume":"3","author":[{"given":"Gaetano","family":"Naso","sequence":"additional","affiliation":[{"name":"Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London WC1N 1EH, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5294-399X","authenticated-orcid":false,"given":"Anastasia","family":"Petrova","sequence":"additional","affiliation":[{"name":"Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London WC1N 1EH, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2019,4,5]]},"reference":[{"key":"2021111608104759200_ETLS-2018-0148CC1","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1038\/jid.2009.108","article-title":"Phenotypic and genotypic analyses of genetic skin disease through the online Mendelian inheritance in man (OMIM) database","volume":"129","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"2021111608104759200_ETLS-2018-0148CC2","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/ddg.13270","article-title":"Research on genodermatoses using novel genome-editing tools","volume":"15","year":"2017","journal-title":"J. Ger. Soc. Dermatol."},{"key":"2021111608104759200_ETLS-2018-0148CC3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/sj.jid.5701040","article-title":"Development of therapeutic siRNAs for pachyonychia congenita","volume":"128","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"2021111608104759200_ETLS-2018-0148CC4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jdermsci.2008.04.003","article-title":"Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita","volume":"51","year":"2008","journal-title":"J. Dermatol. Sci."},{"key":"2021111608104759200_ETLS-2018-0148CC5","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/mt.2009.273","article-title":"First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder","volume":"18","year":"2009","journal-title":"Mol. Ther."},{"key":"2021111608104759200_ETLS-2018-0148CC6","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/jid.2012.28","article-title":"Generic and personalized RNAi-based therapeutics for a dominant-negative epidermal fragility disorder","volume":"132","year":"2012","journal-title":"J. Invest. Dermatol."},{"key":"2021111608104759200_ETLS-2018-0148CC7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.omtn.2018.05.005","article-title":"CRISPR\/Cas9-mediated treatment ameliorates the phenotype of the epidermolytic palmoplantar keratoderma-like mouse","volume":"12","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2021111608104759200_ETLS-2018-0148CC8","doi-asserted-by":"publisher","first-page":"e28582","DOI":"10.1371\/journal.pone.0028582","article-title":"Development of allele-specific therapeutic siRNA in Meesmann epithelial corneal dystrophy","volume":"6","year":"2011","journal-title":"PLoS ONE"},{"key":"2021111608104759200_ETLS-2018-0148CC9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/gt.2015.82","article-title":"Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and in vivo KRT12 mutation-specific targeting","volume":"23","year":"2015","journal-title":"Gene Ther."},{"key":"2021111608104759200_ETLS-2018-0148CC10","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1172\/JCI24834","article-title":"Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer","volume":"115","year":"2005","journal-title":"J. Clin. Invest."},{"key":"2021111608104759200_ETLS-2018-0148CC11","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/hmg\/6.6.927","article-title":"A model of corrective gene transfer in X-linked ichthyosis","volume":"6","year":"1997","journal-title":"Hum. Mol. Genet."},{"key":"2021111608104759200_ETLS-2018-0148CC12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1006\/excr.1993.1326","article-title":"Correction of steroid sulfatase deficiency by gene transfer into basal cells of tissue-cultured epidermis from patients with recessive X-linked ichthyosis","volume":"209","year":"1993","journal-title":"Exp. Cell Res."},{"key":"2021111608104759200_ETLS-2018-0148CC13","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1089\/hum.1997.8.14-1659","article-title":"Direct cutaneous gene delivery in a human genetic skin disease","volume":"8","year":"1997","journal-title":"Hum. Gene Ther."},{"key":"2021111608104759200_ETLS-2018-0148CC14","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/nm1196-1263","article-title":"Corrective gene transfer in the human skin disorder lamellar ichthyosis","volume":"2","year":"1996","journal-title":"Nat. Med."},{"key":"2021111608104759200_ETLS-2018-0148CC15","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jdermsci.2010.12.004","article-title":"rAAV2-mediated restoration of LEKTI in LEKTI-deficient cells from Netherton patients","volume":"61","year":"2011","journal-title":"J. Dermatol. Sci."},{"key":"2021111608104759200_ETLS-2018-0148CC16","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/mt.2010.201","article-title":"Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts","volume":"19","year":"2011","journal-title":"Mol. Ther."},{"key":"2021111608104759200_ETLS-2018-0148CC17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1089\/humc.2013.195","article-title":"Phase I study protocol for ex vivo lentiviral gene therapy for the inherited skin disease, Netherton syndrome","volume":"24","year":"2013","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"2021111608104759200_ETLS-2018-0148CC18","doi-asserted-by":"publisher","first-page":"17759","DOI":"10.1073\/pnas.0406304101","article-title":"Gene transduction in skin cells: preventing cancer in xeroderma pigmentosum mice","volume":"101","year":"2004","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021111608104759200_ETLS-2018-0148CC19","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jbiotec.2006.05.016","article-title":"Functional lentiviral vectors for xeroderma pigmentosum gene therapy","volume":"126","year":"2006","journal-title":"J. Biotechnol."},{"key":"2021111608104759200_ETLS-2018-0148CC20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1023\/A:1007477820594","article-title":"Retrovirus-mediated DNA repair gene transfer into xeroderma pigmentosum cells: perspectives for a gene therapy","volume":"14","year":"1998","journal-title":"Cell Biol. Toxicol."},{"key":"2021111608104759200_ETLS-2018-0148CC21","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1089\/104303403766682241","article-title":"Genetic correction of DNA repair-deficient\/cancer-prone xeroderma pigmentosum group C keratinocytes","volume":"14","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"2021111608104759200_ETLS-2018-0148CC22","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/mt.2011.233","article-title":"Preclinical corrective gene transfer in xeroderma pigmentosum human skin stem cells","volume":"20","year":"2012","journal-title":"Mol. Ther."},{"key":"2021111608104759200_ETLS-2018-0148CC23","doi-asserted-by":"publisher","first-page":"19483","DOI":"10.1073\/pnas.1312088110","article-title":"Repair of UV photolesions in xeroderma pigmentosum group C cells induced by translational readthrough of premature termination codons","volume":"110","year":"2013","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021111608104759200_ETLS-2018-0148CC24","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/exd.12655","article-title":"Readthrough of stop codons by use of aminoglycosides in cells from xeroderma pigmentosum group C patients","volume":"24","year":"2015","journal-title":"Exp. Dermatol."},{"key":"2021111608104759200_ETLS-2018-0148CC25","doi-asserted-by":"publisher","first-page":"e78678","DOI":"10.1371\/journal.pone.0078678","article-title":"Targeted gene therapy of xeroderma pigmentosum cells using meganuclease and TALENTM","volume":"8","year":"2013","journal-title":"PLoS ONE"},{"key":"2021111608104759200_ETLS-2018-0148CC26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature07343","article-title":"Molecular basis of xeroderma pigmentosum group C DNA recognition by engineered meganucleases","volume":"456","year":"2008","journal-title":"Nature"},{"key":"2021111608104759200_ETLS-2018-0148CC27","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1089\/hum.1995.6.10-1307","article-title":"Functional retroviral vector for gene therapy of xeroderma pigmentosum group D patients","volume":"6","year":"1995","journal-title":"Hum. Gene Ther."},{"key":"2021111608104759200_ETLS-2018-0148CC28","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.1093\/hmg\/ddq405","article-title":"K14 mRNA reprogramming for dominant epidermolysis bullosa simplex","volume":"19","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"2021111608104759200_ETLS-2018-0148CC29","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1038\/mt.2010.102","article-title":"Efficient KRT14 targeting and functional characterization of transplanted human keratinocytes for the treatment of epidermolysis bullosa simplex","volume":"18","year":"2010","journal-title":"Mol. Ther."},{"key":"2021111608104759200_ETLS-2018-0148CC30","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1016\/j.ymthe.2017.08.015","article-title":"Cut and paste: efficient homology-directed repair of a dominant negative KRT14 mutation via CRISPR\/Cas9 nickases","volume":"25","year":"2017","journal-title":"Mol. Ther."},{"key":"2021111608104759200_ETLS-2018-0148CC31","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1038\/jid.2011.169","article-title":"Development of allele-specific therapeutic siRNA for keratin 5 mutations in epidermolysis bullosa simplex","volume":"131","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"2021111608104759200_ETLS-2018-0148CC32","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.omtm.2017.06.008","article-title":"Traceless targeting and isolation of gene-edited immortalized keratinocytes from epidermolysis bullosa simplex patients","volume":"6","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2021111608104759200_ETLS-2018-0148CC33","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/sj.jid.5701152","article-title":"5\u2032 Trans-splicing repair of the PLEC1 gene","volume":"128","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"2021111608104759200_ETLS-2018-0148CC34","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/mt.2013.290","article-title":"Somatic correction of junctional epidermolysis bullosa by a highly recombinogenic AAV variant","volume":"22","year":"2014","journal-title":"Mol. Ther."},{"key":"2021111608104759200_ETLS-2018-0148CC35","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature24487","article-title":"Regeneration of the entire human epidermis using transgenic stem cells","volume":"551","year":"2017","journal-title":"Nature"},{"key":"2021111608104759200_ETLS-2018-0148CC36","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/nm1504","article-title":"Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells","volume":"12","year":"2006","journal-title":"Nat. Med."},{"key":"2021111608104759200_ETLS-2018-0148CC37","doi-asserted-by":"publisher","DOI":"10.1002\/9780470015902.a0026940","article-title":"Gene therapy for inherited skin disorders","year":"2017","journal-title":"eLS"},{"key":"2021111608104759200_ETLS-2018-0148CC38","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1038\/mt.2008.204","article-title":"Correction of laminin-5 deficiency in human epidermal stem cells by transcriptionally targeted lentiviral vectors","volume":"16","year":"2008","journal-title":"Mol. Ther."},{"key":"2021111608104759200_ETLS-2018-0148CC39","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/sj.gt.3301978","article-title":"Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer","volume":"10","year":"2003","journal-title":"Gene Ther."},{"key":"2021111608104759200_ETLS-2018-0148CC40","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1016\/j.ymthe.2018.07.024","article-title":"CRISPR\/Cas9-mediated in situ correction of LAMB3 gene in keratinocytes derived from a junctional epidermolysis bullosa patient","volume":"26","year":"2018","journal-title":"Mol. Ther."},{"key":"2021111608104759200_ETLS-2018-0148CC41","doi-asserted-by":"publisher","first-page":"41336","DOI":"10.1074\/jbc.M103139200","article-title":"Gene correction of integrin \u03b24-dependent pyloric atresia-junctional epidermolysis bullosa keratinocytes establishes a role for \u03b24 tyrosines 1422 and 1440 in hemidesmosome assembly","volume":"276","year":"2001","journal-title":"J. Biol. Chem."},{"key":"2021111608104759200_ETLS-2018-0148CC42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/sj.gt.3300809","article-title":"BP180 gene delivery in junctional epidermolysis bullosa","volume":"6","year":"1999","journal-title":"Gene Ther."},{"key":"2021111608104759200_ETLS-2018-0148CC43","doi-asserted-by":"publisher","first-page":"264ra164","DOI":"10.1126\/scitranslmed.3009342","article-title":"Induced pluripotent stem cells from human revertant keratinocytes for the treatment of epidermolysis bullosa","volume":"6","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"2021111608104759200_ETLS-2018-0148CC44","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/mt.2013.56","article-title":"TALEN-based gene correction for epidermolysis bullosa","volume":"21","year":"2013","journal-title":"Mol. Ther."},{"key":"2021111608104759200_ETLS-2018-0148CC45","doi-asserted-by":"publisher","first-page":"946","DOI":"10.3390\/ijms19040946","article-title":"CRISPR\/Cas9-based cellular engineering for targeted gene overexpression","volume":"19","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"2021111608104759200_ETLS-2018-0148CC46","doi-asserted-by":"publisher","first-page":"e307","DOI":"10.1038\/mtna.2016.19","article-title":"Gene editing for the efficient correction of a recurrent COL7A1 mutation in recessive dystrophic epidermolysis bullosa keratinocytes","volume":"5","year":"2016","journal-title":"Mol. Ther. Nucleic Acids."},{"key":"2021111608104759200_ETLS-2018-0148CC47","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/npjregenmed.2016.14","article-title":"CRISPR\/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa","volume":"1","year":"2016","journal-title":"NPJ Regen. Med."},{"key":"2021111608104759200_ETLS-2018-0148CC48","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.omtn.2018.06.008","article-title":"Ex vivo COL7A1 correction for recessive dystrophic epidermolysis bullosa using CRISPR\/Cas9 and homology-directed repair","volume":"12","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2021111608104759200_ETLS-2018-0148CC49","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jid.2015.11.028","article-title":"Meganuclease-mediated COL7A1 gene correction for recessive dystrophic epidermolysis bullosa","volume":"136","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"2021111608104759200_ETLS-2018-0148CC50","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1016\/j.ymthe.2017.07.005","article-title":"COL7A1 editing via CRISPR\/Cas9 in recessive dystrophic epidermolysis bullosa","volume":"25","year":"2017","journal-title":"Mol. Ther."},{"key":"2021111608104759200_ETLS-2018-0148CC51","doi-asserted-by":"publisher","first-page":"B13","DOI":"10.1016\/j.jid.2018.06.078","article-title":"Highly efficient, permanent ex vivo correction of RDEB via non-viral CRISPR\/Cas9 excision of COL7A1 exon 80 bearing a prevalent mutation","volume":"138","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"2021111608104759200_ETLS-2018-0148CC52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.02.015","article-title":"Efficient gene reframing therapy for recessive dystrophic epidermolysis bullosa using CRISPR\/Cas9","year":"2019","journal-title":"J. Invest. Dermatol."},{"key":"2021111608104759200_ETLS-2018-0148CC53","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1038\/jid.2012.11","article-title":"siRNA-mediated allele-specific inhibition of mutant type VII collagen in dominant dystrophic epidermolysis bullosa","volume":"132","year":"2012","journal-title":"J. Invest. Dermatol."},{"key":"2021111608104759200_ETLS-2018-0148CC54","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1038\/jid.2013.241","article-title":"A mutation-independent therapeutic strategy for dominant dystrophic epidermolysis bullosa","volume":"133","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"2021111608104759200_ETLS-2018-0148CC55","doi-asserted-by":"publisher","first-page":"5676","DOI":"10.1073\/pnas.1512028113","article-title":"Site-specific genome editing for correction of induced pluripotent stem cells derived from dominant dystrophic epidermolysis bullosa","volume":"113","year":"2016","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021111608104759200_ETLS-2018-0148CC56","doi-asserted-by":"publisher","first-page":"5665","DOI":"10.1073\/pnas.76.11.5665","article-title":"Growth of cultured human epidermal cells into multiple epithelia suitable for grafting","volume":"76","year":"1979","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021111608104759200_ETLS-2018-0148CC57","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0092-8674(75)80001-8","article-title":"Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells","volume":"6","year":"1975","journal-title":"Cell"},{"key":"2021111608104759200_ETLS-2018-0148CC58","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1001\/jama.2016.15588","article-title":"Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa","volume":"316","year":"2016","journal-title":"J. Am. Med. Assoc."},{"key":"2021111608104759200_ETLS-2018-0148CC59","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/JID.2015.364","article-title":"Lentiviral engineered fibroblasts expressing codon-optimized COL7A1 restore anchoring fibrils in RDEB","volume":"136","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"2021111608104759200_ETLS-2018-0148CC60","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nm1393","article-title":"Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1","volume":"12","year":"2006","journal-title":"Nat. Med."},{"key":"2021111608104759200_ETLS-2018-0148CC61","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1056\/NEJM200301163480314","article-title":"A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency","volume":"348","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"2021111608104759200_ETLS-2018-0148CC62","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1038\/sj.jid.5700435","article-title":"Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients","volume":"126","year":"2006","journal-title":"J. Invest. Dermatol."},{"key":"2021111608104759200_ETLS-2018-0148CC63","doi-asserted-by":"publisher","first-page":"e379","DOI":"10.1038\/mtna.2016.87","article-title":"Antisense oligonucleotide-mediated exon skipping as a systemic therapeutic approach for recessive dystrophic epidermolysis bullosa","volume":"5","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2021111608104759200_ETLS-2018-0148CC64","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1016\/j.jid.2016.07.029","article-title":"Targeted exon skipping restores type VII collagen expression and anchoring fibril formation in an in vivo RDEB model","volume":"136","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"2021111608104759200_ETLS-2018-0148CC65","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.molonc.2013.08.005","article-title":"The design and optimization of RNA trans-splicing molecules for skin cancer therapy","volume":"7","year":"2013","journal-title":"Mol. Oncol."},{"key":"2021111608104759200_ETLS-2018-0148CC66","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/gt.2016.57","article-title":"Construction and validation of an RNA trans-splicing molecule suitable to repair a large number of COL7A1 mutations","volume":"23","year":"2016","journal-title":"Gene Ther."},{"key":"2021111608104759200_ETLS-2018-0148CC67","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00018-015-2075-z","article-title":"Xeroderma pigmentosum group C sensor: unprecedented recognition strategy and tight spatiotemporal regulation","volume":"73","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"2021111608104759200_ETLS-2018-0148CC68","doi-asserted-by":"publisher","first-page":"24429","DOI":"10.1074\/jbc.M003440200","article-title":"Development and characterization of a recombinant truncated type VII collagen \u201cminigene\u201d. Implication for gene therapy of dystrophic epidermolysis bullosa","volume":"275","year":"2000","journal-title":"J. Biol. Chem."},{"key":"2021111608104759200_ETLS-2018-0148CC69","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2174\/156652311794520111","article-title":"Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy","volume":"11","year":"2011","journal-title":"Curr. Gene Ther."},{"key":"2021111608104759200_ETLS-2018-0148CC70","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"2021111608104759200_ETLS-2018-0148CC71","first-page":"636","article-title":"TAL effectors: customizable proteins for DNA targeting","volume":"5","year":"2011","journal-title":"Science"},{"key":"2021111608104759200_ETLS-2018-0148CC72","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","year":"2014","journal-title":"Cell"},{"key":"2021111608104759200_ETLS-2018-0148CC73","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","year":"2012","journal-title":"Science"},{"key":"2021111608104759200_ETLS-2018-0148CC74","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/mt.2016.5","article-title":"Current progress in therapeutic gene editing for monogenic diseases","volume":"24","year":"2016","journal-title":"Mol. Ther."},{"key":"2021111608104759200_ETLS-2018-0148CC75","doi-asserted-by":"publisher","first-page":"5809","DOI":"10.1073\/pnas.0800940105","article-title":"Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases","volume":"105","year":"2008","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021111608104759200_ETLS-2018-0148CC76","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.jaad.2014.01.903","article-title":"Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification","volume":"70","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"2021111608104759200_ETLS-2018-0148CC77","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/bjd.13190","article-title":"Whole-exome sequencing improves mutation detection in a diagnostic epidermolysis bullosa laboratory","volume":"172","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"2021111608104759200_ETLS-2018-0148CC78","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/mt.2010.91","article-title":"SIN retroviral vectors expressing COL7A1 under human promoters for Ex vivo gene therapy of recessive dystrophic epidermolysis bullosa","volume":"18","year":"2010","journal-title":"Mol. Ther."},{"key":"2021111608104759200_ETLS-2018-0148CC79","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1089\/humc.2014.2508","article-title":"Phase I\/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector (GENEGRAFT)","volume":"25","year":"2014","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"2021111608104759200_ETLS-2018-0148CC80","unstructured":"A study of FCX-007 for recessive dystrophic epidermolysis bullosa (RDEB) \u2013 full text view \u2013 ClinicalTrials.gov [Internet]. [cited 2019 Jan 7]"},{"key":"2021111608104759200_ETLS-2018-0148CC81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/scrt511","article-title":"Preconditioning of mesenchymal stem cells for improved transplantation efficacy in recessive dystrophic epidermolysis bullosa","volume":"5","year":"2014","journal-title":"Stem Cell Res. Ther."},{"key":"2021111608104759200_ETLS-2018-0148CC82","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1038\/mt.2015.58","article-title":"High local concentrations of intradermal MSCs restore skin integrity and facilitate wound healing in dystrophic epidermolysis bullosa","volume":"23","year":"2015","journal-title":"Mol. Ther."},{"key":"2021111608104759200_ETLS-2018-0148CC83","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jdermsci.2018.06.004","article-title":"The development of induced pluripotent stem cell-derived mesenchymal stem\/stromal cells from normal human and RDEB epidermal keratinocytes","volume":"91","year":"2018","journal-title":"J. Dermatol. Sci."},{"key":"2021111608104759200_ETLS-2018-0148CC84","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1038\/jid.2015.158","article-title":"Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epidermolysis bullosa","volume":"135","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"2021111608104759200_ETLS-2018-0148CC85","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3109\/14653241003587637","article-title":"Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa","volume":"12","year":"2010","journal-title":"Cytotherapy"},{"key":"2021111608104759200_ETLS-2018-0148CC86","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1182\/blood-2008-06-161299","article-title":"Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells","volume":"113","year":"2009","journal-title":"Blood"},{"key":"2021111608104759200_ETLS-2018-0148CC87","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa0910501","article-title":"Bone marrow transplantation for recessive dystrophic epidermolysis bullosa","volume":"363","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"2021111608104759200_ETLS-2018-0148CC88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.3009540","article-title":"Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa","volume":"6","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"2021111608104759200_ETLS-2018-0148CC89","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1073\/pnas.0711983105","article-title":"Generation of human induced pluripotent stem cells from dermal fibroblasts","volume":"105","year":"2008","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021111608104759200_ETLS-2018-0148CC90","doi-asserted-by":"publisher","first-page":"264ra165","DOI":"10.1126\/scitranslmed.3010083","article-title":"Genetically corrected iPSCs as cell therapy for recessive dystrophic epidermolysis bullosa","volume":"6","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"2021111608104759200_ETLS-2018-0148CC91","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/jid.2010.346","article-title":"Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa","volume":"131","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"2021111608104759200_ETLS-2018-0148CC92","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.omtn.2018.01.009","article-title":"Deletion of a pathogenic mutation-containing exon of COL7A1 allows clonal gene editing correction of RDEB patient epidermal stem cells","volume":"11","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2021111608104759200_ETLS-2018-0148CC93","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/labinvest.2017.85","article-title":"Rapid generation of Col7a1\u2212\/\u2212 mouse model of recessive dystrophic epidermolysis bullosa and partial rescue via immunosuppressive dermal mesenchymal stem cells","volume":"97","year":"2017","journal-title":"Lab. Invest."},{"key":"2021111608104759200_ETLS-2018-0148CC94","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1073\/pnas.1614775114","article-title":"Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model","volume":"114","year":"2017","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021111608104759200_ETLS-2018-0148CC95","doi-asserted-by":"publisher","first-page":"400341","DOI":"10.1101\/400341","article-title":"Mutations generated by repair of Cas9-induced double strand breaks are predictable from surrounding sequence","year":"2018","journal-title":"bioRxiv"},{"key":"2021111608104759200_ETLS-2018-0148CC96","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41586-018-0686-x","article-title":"Predictable and precise template-free CRISPR editing of pathogenic variants","volume":"563","year":"2018","journal-title":"Nature"},{"key":"2021111608104759200_ETLS-2018-0148CC97","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1089\/104303400750035825","article-title":"Toward epidermal stem cell-mediated ex vivo gene therapy of junctional epidermolysis bullosa","volume":"11","year":"2000","journal-title":"Hum. Gene Ther."},{"key":"2021111608104759200_ETLS-2018-0148CC98","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0918-899c","article-title":"Repair of double-strand breaks induced by CRISPR\u2013Cas9 leads to large deletions and complex rearrangements","volume":"36","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"2021111608104759200_ETLS-2018-0148CC99","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage","volume":"551","year":"2017","journal-title":"Nature"},{"key":"2021111608104759200_ETLS-2018-0148CC100","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","year":"2016","journal-title":"Nature"},{"key":"2021111608104759200_ETLS-2018-0148CC101","doi-asserted-by":"publisher","first-page":"eaao4774","DOI":"10.1126\/sciadv.aao4774","article-title":"Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity","volume":"3","year":"2017","journal-title":"Sci Adv."},{"key":"2021111608104759200_ETLS-2018-0148CC102","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf7573","article-title":"Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems","volume":"353","year":"2016","journal-title":"Science"},{"key":"2021111608104759200_ETLS-2018-0148CC103","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nbt.3803","article-title":"Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions","volume":"35","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"2021111608104759200_ETLS-2018-0148CC104","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base editing: precision chemistry on the genome and transcriptome of living cells","volume":"19","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"2021111608104759200_ETLS-2018-0148CC105","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/humu.21651","article-title":"The COL7A1 mutation database","volume":"33","year":"2012","journal-title":"Hum. Mutat."},{"key":"2021111608104759200_ETLS-2018-0148CC106","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.molcel.2017.08.008","article-title":"CRISPR-mediated base editing enables efficient disruption of eukaryotic genes through induction of STOP codons","volume":"67","year":"2017","journal-title":"Mol. Cell."},{"key":"2021111608104759200_ETLS-2018-0148CC107","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/nmeth.4327","article-title":"CRISPR-STOP: gene silencing through base-editing-induced nonsense mutations","volume":"14","year":"2017","journal-title":"Nat. Methods"},{"key":"2021111608104759200_ETLS-2018-0148CC108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-018-1482-5","article-title":"CRISPR-SKIP: programmable gene splicing with single base editors","volume":"19","year":"2018","journal-title":"Genome Biol."},{"key":"2021111608104759200_ETLS-2018-0148CC109","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In vivo genome editing using Staphylococcus aureus Cas9","volume":"520","year":"2015","journal-title":"Nature"},{"key":"2021111608104759200_ETLS-2018-0148CC110","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.cell.2015.09.038","article-title":"Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system","volume":"163","year":"2015","journal-title":"Cell"},{"key":"2021111608104759200_ETLS-2018-0148CC111","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature26155","article-title":"Evolved Cas9 variants with broad PAM compatibility and high DNA specificity","volume":"556","year":"2018","journal-title":"Nature"},{"key":"2021111608104759200_ETLS-2018-0148CC112","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","article-title":"Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9","volume":"34","year":"2016"},{"key":"2021111608104759200_ETLS-2018-0148CC113","first-page":"233","article-title":"Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation","volume":"1","year":"2012"},{"key":"2021111608104759200_ETLS-2018-0148CC114","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1101\/gr.191452.115","article-title":"Sequence determinants of improved CRISPR sgRNA design","volume":"25","year":"2015","journal-title":"Genome Res."},{"key":"2021111608104759200_ETLS-2018-0148CC115","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nbt.2808","article-title":"Improving CRISPR-Cas nuclease specificity using truncated guide RNAs","volume":"32","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"2021111608104759200_ETLS-2018-0148CC116","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","article-title":"Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity","volume":"154","year":"2013","journal-title":"Cell"},{"key":"2021111608104759200_ETLS-2018-0148CC117","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nature16526","article-title":"High-fidelity CRISPR\u2013Cas9 nucleases with no detectable genome-wide off-target effects","volume":"529","year":"2016","journal-title":"Nature"},{"key":"2021111608104759200_ETLS-2018-0148CC118","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.aad5227","article-title":"Rationally engineered Cas9 nucleases with improved specificity","volume":"351","year":"2016"},{"key":"2021111608104759200_ETLS-2018-0148CC119","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3389\/fphar.2018.00749","article-title":"The current state and future of CRISPR-Cas9 gRNA design tools","volume":"9","year":"2018","journal-title":"Front. Pharmacol."},{"key":"2021111608104759200_ETLS-2018-0148CC120","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13059-018-1459-4","article-title":"DeepCRISPR: optimized CRISPR guide RNA design by deep learning","volume":"19","year":"2018","journal-title":"Genome Biol."},{"key":"2021111608104759200_ETLS-2018-0148CC121","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nmeth.3284","article-title":"Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells","volume":"12","year":"2015","journal-title":"Nat. Methods"},{"key":"2021111608104759200_ETLS-2018-0148CC122","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nmeth.2408","article-title":"Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing","volume":"10","year":"2013","journal-title":"Nat. Methods"},{"key":"2021111608104759200_ETLS-2018-0148CC123","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nbt.3117","article-title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases","volume":"33","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"2021111608104759200_ETLS-2018-0148CC124","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nm1063","article-title":"Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa","volume":"10","year":"2004","journal-title":"Nat. Med."},{"key":"2021111608104759200_ETLS-2018-0148CC125","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1038\/jid.2013.10","article-title":"Intravenously injected recombinant human type VII collagen homes to skin wounds and restores skin integrity of dystrophic epidermolysis bullosa","volume":"133","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"2021111608104759200_ETLS-2018-0148CC126","doi-asserted-by":"publisher","first-page":"e287","DOI":"10.1038\/mtna.2016.3","article-title":"A gene Gun-mediated nonviral RNA trans-splicing strategy for Col7a1 repair","volume":"5","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2021111608104759200_ETLS-2018-0148CC127","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1039\/C6BM00441E","article-title":"Recent progress in nanomaterials for gene delivery applications","volume":"4","year":"2016","journal-title":"Biomater. Sci."}],"container-title":["Emerging Topics in Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/emergtoplifesci\/article-pdf\/3\/3\/313\/851053\/etls-2018-0148c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/emergtoplifesci\/article-pdf\/3\/3\/313\/851053\/etls-2018-0148c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T08:10:54Z","timestamp":1637050254000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/emergtoplifesci\/article\/3\/3\/313\/219701\/CRISPR-Cas9-gene-editing-for-genodermatoses"}},"subtitle":[],"editor":[{"given":"Waseem","family":"Qasim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,4,5]]},"references-count":127,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,4,5]]},"published-print":{"date-parts":[[2019,5,31]]}},"URL":"https:\/\/doi.org\/10.1042\/etls20180148","relation":{},"ISSN":["2397-8554","2397-8562"],"issn-type":[{"value":"2397-8554","type":"print"},{"value":"2397-8562","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,5]]}}}